Back to mobile site

Pacira Pharma (PCRX): AdComm Votes 6:4 No for Nerve Block sNDA Approval, PT To $72 - Wedbush

February 16, 2018 7:04 AM EST Send to a Friend
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) and cut her price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login